Effectiveness of PRP, Conditioned Medium UC-MSCs Secretome and Hyaluronic Acid for the Treatment of Knee Osteoarthritis

Launched by UNIVERSITAS SRIWIJAYA · Oct 11, 2022

Keywords

ClinConnect Summary

In this, prospective, Open-label study, patients with mild to moderate symptomatic knee osteoarthritis will be randomized to receive either a series of platelet-rich plasma or hyaluronic acid or Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell (MSC) Culture Secretome injections under ultrasound guidance. Each of the groups were given 5 times injection 3 cc platelet-rich plasma or 2 cc hyaluronic acid or 2cc Conditioned Medium From Umbilical Cord MSC Secretome at intervals 1 weeks.

Clinical data in the form of subjective outcome measures will be collected pre-treatment and 6 mon...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 30-60 years
• • Suffering from grade 2 and 3 osteoarthritis (OA) was identified by two observers who differed accordingly the Kellgren and Lawrence research scale
• • Patient with knee pain that had been continuing for at least 12 months with no relief using anti-inflammatory medications and that deteriorated with weight-bearing
• • Patients can understand the nature of the study and written informed consent is given to patients
• Exclusion Criteria:
• • Age \> 60 years
• • Acute Knee Osteoarthritis Effusions
• • Patients are not willing to obey the study protocol
• • There are signs of infection local or general infection or positive serology for HIV, hepatitis and syphilis
• • There is a congenital disease that causes significant deformity of the knee can interfere with cell applications and interpret results
• • Articular injection of the knee by any drug during the previous 3 months
• • Participate in any clinical trial or treatment 30 days before the study
• • Other conditions may, according to medical criteria, not support participation in this research (The recent history of knee trauma, Autoimmune rheumatic diseases, Uncontrolled systemic diseases such as diabetes or hypertension, patient with Immunosuppressive or anticoagulant treatment and cancer)